| Name | Title | Contact Details |
|---|---|---|
Edward Ryan |
Sr. Dir, IT, Office of CIO | Profile |
Annlea Rumfola |
EVP, Chief Information Officer | Profile |
Heather Knight |
Chief Operating Officer | Profile |
Chris Toth |
Chief Executive Officer | Profile |
Carl Jenkins |
Associate General Counsel, Legal-Regulatory | Profile |
Palette Life Sciences is a fully integrated medical device company providing a wide range of products and services that improve quality of life of patients. Our portfolio of products focuses on treating conditions in urology/urogynecology disorders, colorectal conditions, radiotherapy, and interventional oncology procedures. For physicians, researchers, and inventors alike, progress begins with a natural curiosity and the drive to do more. By discovering and applying new applications of proven medicine to uncommon, or difficult to treat conditions, we can address the needs of patients often overlooked by traditional medical companies. Inspired by innovation and empathy, we see endless possibilities in expanding on proven technologies to elevate patient care. The foundation for all of our breakthrough products is Non-Animal Stabilized Hyaluronic Acid (NASHA®). NASHA has been proven safe and effective for more than two decades in over 50 million medical procedures worldwide. Barrigel® - the first and only FDA-cleared hyaluronic acid rectal spacer, minimizing the side effects of radiation therapy for prostate cancer patients. Barrigel is available in the US, Australia and Europe. Deflux® - the only FDA-approved injectable treatment for vesicoureteral reflux (VUR), a urinary defect that affects 1% of children worldwide. Deflux for VUR is available in the US, Canada, Europe, Japan, Latin America, Australia and New Zealand. Also indicated for stress urinary incontinence (SUI) in women, Deflux for SUI is available in Canada and Europe.
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific`s system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing.
Labnics Equipment is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Asian Medical is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rocky Mountain Lions Eye Bank is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.